col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer-Verlag: Drug Safety
  original article Date Title Authors   All Authors
1 [GO] 2021―Nov―05 COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety Nicoletta Luxi, Alexia Giovanazzi, Annalisa Capuano, Salvatore Crisafulli, Paola Maria Cutroneo, Maria Pia Fantini, et al. (+118)
2 [GO] 2021―Aug―17 Inconsistent Safety Outcome Reporting in Randomized Clinical Trials of COVID-19 Vaccines Complicates Informed Medical Decisions Joseph E. Blais, Yue Wei, Celine S. L. Chui, Esther W. Chan, Ian C. K. Wong
3 [GO] 2021―Aug―10 Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020 Elena Rocca, Oskar Gauffin, Ruth Savage, Sara Hedfors Vidlin, Birgitta Grundmark
4 [GO] 2021―Aug―04 Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report Toyotaka Iguchi, Hikari Umeda, Michie Kojima, Yuri Kanno, Yuta Tanaka, Natsumi Kinoshita, Daisaku Sato
5 [GO] 2021―Aug―02 NSAIDs and COVID-19: A Systematic Review and Meta-analysis Nicholas Moore, Pauline Bosco-Levy, Nicolas Thurin, Patrick Blin, Cécile Droz-Perroteau
6 [GO] 2021―Apr―16 Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review Subhrojyoti Bhowmick, Amit Dang, B. N. Vallish, Sumit Dang
7 [GO] 2021―Mar―05 Safety Consequences of Off-Label Drugs Used for COVID-19 Nabarun Dasgupta
8 [GO] 2021―Feb―19 Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer Helen Petousis-Harris
9 [GO] 2020―Dec―28 French Pharmacovigilance Public System and COVID-19 Pandemic Aurélie Grandvuillemin, Milou-Daniel Drici, Annie Pierre Jonville-Bera, Joelle Micallef, Jean Louis Montastruc
10 [GO] 2020―Dec―22 Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s Perspective Elena Beyzarov, Yan Chen, Rob Julg, Karen Naim, Jigna Shah, William W. Gregory, et al. (+2)
11 [GO] 2020―Nov―27 Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19 Catia Marzolini, Felix Stader, Anne Leuppi-Taegtmeyer, Marcel Stoeckle, Manuel Battegay, Parham Sendi
12 [GO] 2020―Nov―21 How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine Saad Shakir, Samantha Lane, Miranda Davies
13 [GO] 2020―Oct―19 Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study Philippe Garcia, Alexis Revet, Antoine Yrondi, Vanessa Rousseau, Yannick Degboe, François Montastruc
14 [GO] 2020―Sep―30 Assessing the Safety of COVID-19 Vaccines: A Primer Helen Petousis-Harris
15 [GO] 2020―Sep―25 Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports Alem Zekarias, Sarah Watson, Sara Hedfors Vidlin, Birgitta Grundmark
16 [GO] 2020―Aug―27 Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients Gianluca Trifirò, Marco Massari, Roberto Da Cas, Francesca Menniti Ippolito, Janet Sultana, Salvatore Crisafulli, et al. (+7)
17 [GO] 2020―Jul―21 Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines Janet Sultana, Paola Maria Cutroneo, Salvatore Crisafulli, Gabriele Puglisi, Gaetano Caramori, Gianluca Trifirò
18 [GO] 2020―Jun―23 Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment Vicki Osborne, Miranda Davies, Samantha Lane, Alison Evans, Jacqueline Denyer, Sandeep Dhanda, et al. (+2)
19 [GO] 2020―Jun―22 The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Daniele Focosi, Corrado Blandizzi
20 [GO] 2020―Jun―11 Does Ibuprofen Worsen COVID-19? Nicholas Moore, Bruce Carleton, Patrick Blin, Pauline Bosco-Levy, Cecile Droz
21 [GO] 2020―Jun―08 Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same Alexandre Olry, Lucy Meunier, Bénédicte Délire, Dominique Larrey, Yves Horsmans, Hervé Le Louët
22 [GO] 2020―May―28 Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment Miranda Davies, Vicki Osborne, Samantha Lane, Debabrata Roy, Sandeep Dhanda, Alison Evans, Saad Shakir
23 [GO] 2020―May―07 The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic Rebecca E Chandler, Deirdre McCarthy, Jean-Christophe Delumeau, Mira Harrison-Woolrych
24 [GO] 2020―Apr―17 Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Gianluca Trifirò, Salvatore Crisafulli, Giuseppe Andò, Giorgio Racagni, Filippo Drago
25 [GO] 2020―Apr―07 Chloroquine for COVID-19 Infection Nicholas Moore


Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.005 sec